SCHEMBL22772385

SCHEMBL22772385

C#Cc1cccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 6/20 0.70
MAPT P10636 1/20 0.59
LCK P06239 1/20 0.57
TEK Q02763 1/20 0.57
LMNA P02545 1/20 0.55
ABL1 P00519 1/20 0.54
BCR P11274 1/20 0.54
TRPA1 O75762 1/20 0.53
CYP1A2 P05177 1/20 0.53
RHOC P08134 1/20 0.53
RHOA P61586 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
KCNK3 O14649 1/20 0.52
P2RX4 Q99571 2/20 0.52
P2RX7 Q99572 2/20 0.52
TLR7 Q9NYK1 1/20 0.52
TMPRSS4 Q9NRS4 1/20 0.52
PTGS1 P23219 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17936093 0.91 MAPT (0.74) P2RX1MAPTLCKTEKLMNA
SCHEMBL22772362 0.86 RHOC (0.60) P2RX1MAPTLMNAABL1BCR
SCHEMBL17818404 0.85 MAPT (0.70) P2RX1MAPTLCKTEKLMNA
SCHEMBL12412184 0.83 GRM5 (0.58) P2RX1MAPTLCKTEK
SCHEMBL5227631 0.83 P2RX1 (1.00) P2RX1MAPTLMNARHOCRHOA
SCHEMBL17818365 0.82 MAPT (0.66) P2RX1MAPTLMNARXFP1KCNK3
SCHEMBL12412171 0.81 GRM5 (0.60) P2RX1LCKTEKLMNATRPA1
SCHEMBL3838614 0.81 HDAC1 (0.66) P2RX1MAPTRXFP1KCNK3
SCHEMBL13692719 0.81 HDAC8 (0.52) LMNAKCNK3PTGS1
SCHEMBL22772369 0.81 NR2E1 (0.75) ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407745-B2 Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-08-09 US disclosed
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-17 US disclosed
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME ABL1, DDR1, ABL2 P2RX1 3220/4885MAPT 3839/4885LCK 34/4885
US-11407745-B2 Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same ABL1, DDR1, ABL2 P2RX1 3084/4885MAPT 3859/4885LCK 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.